<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy in advanced castration-resistant prostate cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy in advanced castration-resistant prostate cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chemotherapy in advanced castration-resistant prostate cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arif Hussain, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Dawson, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">A Oliver Sartor, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>For men with advanced prostate cancer, androgen deprivation therapy (ADT) usually can provide disease control for a substantial period of time. However, the vast majority of men eventually develop progressive disease that is resistant to further hormonal treatment (castration-resistant prostate cancer [CRPC]), and typically metastatic.</p><p>Prior to the development of the taxanes, cytotoxic chemotherapy was considered to be relatively ineffective in men with CRPC. In early trials, objective response rates were 10 to 20 percent, and median survival generally did not exceed 12 months.</p><p>However, taxane-based regimens have been associated with higher rates of objective tumor regression and biochemical (prostate-specific antigen [PSA]) response, as well as longer overall survival. As discussed below, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> has an established role in chemotherapy-naïve patients, and a second-generation taxane, <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a>, is active in patients who have received prior docetaxel.</p><p>The use of cytotoxic chemotherapy for the treatment of CRPC will be reviewed here. The use of chemotherapy in combination with ADT for castration-sensitive disease is discussed separately, as are the benefits of treatments for CRPC targeting the androgen pathway, immunotherapy, poly(ADP-ribose) polymerase (PARP) inhibitors for men with homologous recombination repair deficiency, and experimental approaches. An overview of our approach to selecting among the various treatments for CRPC and a discussion about the sequencing of the different treatments (a suggested approach is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef121681" href="/z/d/graphic/121681.html" rel="external">algorithm 1</a>)) are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">"Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer"</a> and  <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">"Castration-resistant prostate cancer: Treatments targeting the androgen pathway"</a> and  <a class="medical medical_review" href="/z/d/html/6937.html" rel="external">"Immunotherapy for castration-resistant prostate cancer"</a> and  <a class="medical medical_review" href="/z/d/html/128308.html" rel="external">"Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">"Overview of the treatment of castration-resistant prostate cancer (CRPC)"</a>.)</p><p class="headingAnchor" id="H503635289"><span class="h1">GERMLINE AND TARGETED TUMOR GENOMIC TESTING</span><span class="headingEndMark"> — </span>Increasingly, biomarker expression is driving therapeutic decision making in patients with advanced refractory cancer, including CRPC. For patients with metastatic CRPC who would be candidates for targeted therapies, both germline genomic testing (if not already known) and somatic genomic testing (gene profiling of tumor tissue using multigene panel-based assays) should be undertaken because of the significant treatment implications, particularly of finding alterations in homologous recombination repair genes [<a href="#rid1">1,2</a>]. (See <a class="local">'Men with homologous recombination repair gene aberrations'</a> below.)</p><p>ASCO has issued a provisional clinical opinion that supports germline and somatic genomic testing in metastatic or advanced cancer when there are genomic biomarker-linked therapies approved by regulatory agencies for their cancer [<a href="#rid2">2</a>]. Given the tissue-agnostic approvals for any advanced cancer with a high tumor mutational burden or DNA mismatch repair deficiency (checkpoint inhibitor immunotherapy), or neurotrophic tyrosine receptor kinase (NTRK) fusions (TRK inhibitors), in principle this provides a rationale for genomic testing of all solid tumors, if the individual would be a candidate for these treatments. Testing should also be considered to determine candidacy for targeted therapies approved for other diseases in patients without approved genomic biomarker-linked therapy; however off-label/off-study use of such therapies is not recommended when a clinical trial is available, or without evidence of meaningful efficacy in clinical trials. (See  <a class="medical medical_review" href="/z/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications", section on 'Cancer screening and management'</a> and  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a> and  <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy"</a>.)</p><p class="headingAnchor" id="H3912327340"><span class="h1">MEN WITHOUT GERMLINE OR SOMATIC DNA REPAIR GENE ABERRATIONS</span></p><p class="headingAnchor" id="H8"><span class="h2">Chemotherapy-naïve patients</span></p><p class="headingAnchor" id="H3320913302"><span class="h3">Castration-resistant disease</span><span class="headingEndMark"> — </span>For men with chemotherapy-naïve CRPC without neuroendocrine (small cell) features who are candidates for cytotoxic chemotherapy, we recommend <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> (75 mg/m<sup>2</sup> every three weeks) rather than <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a>. (See <a class="local">'Docetaxel versus mitoxantrone'</a> below.)</p><p class="bulletIndent1">For most men, we generally prefer <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> over <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> as the initial chemotherapy regimen. Cabazitaxel (20 mg/m<sup>2</sup>) may be preferred in older or frail patients and those at high risk for neutropenia, based on its lower toxicity and equal efficacy compared with docetaxel, despite its higher cost. (See <a class="local">'Docetaxel versus cabazitaxel'</a> below.)</p><p></p><p>Another alternative for patients in whom myelosuppression is of particular concern is administration of a lower <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> dose (50 mg/m<sup>2</sup>) every two weeks. (See <a class="local">'Alternative docetaxel schedules'</a> below.)</p><p>Gonadal androgen suppression, but not antiandrogens, should be continued during chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/6942.html" rel="external">"Alternative endocrine therapies for castration-resistant prostate cancer", section on 'Continuation of androgen deprivation therapy'</a>.)</p><p>The activity of taxanes in men with CRPC was initially suggested by multiple phase II studies in which <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, with or without <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, was given on either a weekly or every-three-week schedule. These trials led to the evaluation of docetaxel in a number of combinations, including a phase III comparison with <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a>, which established the combination of docetaxel plus prednisone as the standard of care for initial chemotherapy in men with CRPC [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H9"><span class="h4">Docetaxel versus mitoxantrone</span><span class="headingEndMark"> — </span>In the TAX-327 trial, 1006 men with chemotherapy-naïve metastatic CRPC were randomly assigned to <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> 75 mg/m<sup>2</sup> every three weeks, docetaxel 30 mg/m<sup>2</sup> weekly, or <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> 12 mg/m<sup>2</sup> every three weeks [<a href="#rid4">4</a>]. All patients received <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 5 mg orally twice a day. Patients were continued on maintenance gonadal androgen suppression, but antiandrogens were discontinued at least four weeks prior to chemotherapy. Overall survival was the primary endpoint of the trial. (See  <a class="medical medical_review" href="/z/d/html/6942.html" rel="external">"Alternative endocrine therapies for castration-resistant prostate cancer", section on 'Continuation of androgen deprivation therapy'</a>.) </p><p>Key results from the trial included the following:</p><p class="bulletIndent1"><span class="glyph">●</span>With an extended follow-up that included death of 86 percent of the patients, the benefit of the every-three-week schedule of <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> persisted for overall survival (median 19.2 versus 17.8 and 16.3 months for the weekly docetaxel and <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> regimens, respectively) [<a href="#rid5">5</a>]. The three-year survival rates were higher in those treated with the two docetaxel schedules (18.6 and 16.6 versus 13.5 percent with mitoxantrone, respectively). Crossover to the alternative chemotherapy agent was permitted and may have influenced overall survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In subset analyses, survival benefits were present in those older and younger than 65 years of age, in those with and without pain at baseline, and in those whose baseline prostate-specific antigen (PSA) was greater than or less than the median (115 ng/mL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both the <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> treatment schedules were associated with a higher PSA response rate than <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> (45 and 48 versus 32 percent, respectively) and a higher pain response rate (35 and 31 versus 22 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade 3 or 4 neutropenia was most common with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> every three weeks compared with weekly docetaxel and <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> (32 versus 2 and 22 percent). Neutropenic infection was uncommon with all three regimens (3, 0, and 2 percent, respectively). Discontinuation of treatment due to adverse effects was uncommon with all three regimens (11, 16, and 10 percent, respectively).</p><p></p><p><a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">Dexamethasone</a> (8 mg) was administered 12, 3, and 1 hour(s) prior to infusion with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> to minimize toxicity. Although some have speculated that the dexamethasone, rather than the docetaxel, may be responsible for the activity of this combination [<a href="#rid6">6</a>], at least one study found no benefit from dexamethasone alone [<a href="#rid7">7</a>].</p><p>These results established <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> (75 mg/m<sup>2</sup> every three weeks) plus daily <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (5 mg twice a day) as the standard of care for initial systemic chemotherapy for men with CRPC.</p><p class="headingAnchor" id="H196091783"><span class="h4">Alternative docetaxel schedules</span><span class="headingEndMark"> — </span>Alternative approaches using <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> have been studied in randomized trials, but the every-three-week schedule in conjunction with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> remains the standard of care for initial systemic therapy of men with CRPC.</p><p>For patients who are unlikely to tolerate <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> on an every-three-week schedule, more frequent administration of docetaxel may offer a less myelosuppressive alternative. In a phase III trial, 361 patients were randomly assigned to docetaxel 50 mg/m<sup>2</sup> every two weeks or to docetaxel 75 mg/m<sup>2</sup> every three weeks, both given with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid8">8</a>]. The every-two-week schedule was associated with significantly improved time to treatment failure (5.6 versus 4.9 months) and overall survival compared with the every-three-week schedule (19.5 versus 17.0 months), and there was a decrease in the incidence of severe neutropenia (53 versus 36 percent) and febrile neutropenia (14 versus 4 percent). Based on these results, although the three-week schedule is well established and more convenient, docetaxel every two weeks at the reduced dose could be an alternative for patients in whom myelosuppression is of particular concern.</p><p class="headingAnchor" id="H10"><span class="h4">Other docetaxel combinations</span><span class="headingEndMark"> — </span>Multiple large phase III trials have failed to demonstrate an improvement in overall survival from adding other agents to the <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>/<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> regimen. Agents tested include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular endothelial growth factor inhibition (<a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> [<a href="#rid9">9</a>], <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a> [<a href="#rid10">10</a>])</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">Lenalidomide</a> [<a href="#rid11">11</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">Dasatinib</a> [<a href="#rid12">12</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Endothelin receptor antagonists (atrasentan [<a href="#rid13">13</a>], zibotentan [<a href="#rid14">14</a>])</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">Calcitriol</a> [<a href="#rid15">15</a>]</p><p></p><p>Docetaxel-based combinations with older cytotoxic agents (<a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">vinorelbine</a> [<a href="#rid16">16</a>], <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> [<a href="#rid17">17</a>], <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">epirubicin</a> [<a href="#rid18">18</a>], and <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> [<a href="#rid19">19</a>]) have been evaluated in a more limited way in phase II studies, but none of these has an established role.</p><p class="headingAnchor" id="H3764475825"><span class="h4">Docetaxel versus cabazitaxel</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">Docetaxel</a> is generally preferred over <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> as the initial chemotherapy regimen for chemotherapy-naïve patients. However, cabazitaxel (20 mg/m<sup>2</sup>) may be preferred in older or frail patients and those at high risk for neutropenia, based on its lower toxicity and similar efficacy, despite its higher cost. If neutropenia is a problem with docetaxel, the addition of a granulocyte colony-stimulating factor (G-CSF) to docetaxel is another option. (See  <a class="medical medical_review" href="/z/d/html/14257.html" rel="external">"Prostate cancer in older males", section on 'Metastatic castration-resistant prostate cancer'</a> and  <a class="medical medical_review" href="/z/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation"</a>.)</p><p>Based on its ability to prolong overall survival in patients who had docetaxel-resistant disease, <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> was compared with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> in chemotherapy-naïve patients. (See <a class="local">'Cabazitaxel'</a> below.)</p><p>In a phase III trial, 1168 men with castration-resistant disease were randomly assigned to one of three treatment arms: <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> 20 mg/m<sup>2</sup>, cabazitaxel 25 mg/m<sup>2</sup>, or <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> 75 mg/m<sup>2</sup> [<a href="#rid20">20</a>]. For each treatment arm, the drug was administered every three weeks in conjunction with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>.</p><p class="bulletIndent1"><span class="glyph">●</span>There were no statistically significant differences in overall survival, the primary endpoint of the study, between the three treatment arms (median 24.5 months for <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> 20 mg/m<sup>2</sup>, 25.2 months for cabazitaxel 25 mg/m<sup>2</sup>, and 24.3 months for <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the tumor response rate was significantly higher with <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> 25 mg/m<sup>2</sup> compared with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> (42 versus 31 percent), there was no significant difference between the three treatment arms in progression-free survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of grade 3 or 4 toxicity with <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> 20 mg/m<sup>2</sup>, cabazitaxel 25 mg/m<sup>2</sup>, and <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> 75 mg/m<sup>2</sup> was 41, 60, and 46 percent, respectively. The incidence of febrile neutropenia was lower with cabazitaxel 20 mg/m<sup>2</sup> compared with the other two regimens (2.4 versus 12.0 and 8.3 percent, respectively). Hematuria was more frequent with cabazitaxel, while peripheral neuropathy, edema, alopecia, and nail disorders were more frequent with docetaxel.</p><p></p><p class="headingAnchor" id="H4038987900"><span class="h3">Castration-sensitive disease</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">Docetaxel</a> has been shown to increase overall survival in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic castration-sensitive prostate cancer. The role of docetaxel plus ADT in this setting is discussed separately.</p><p class="headingAnchor" id="H12"><span class="h2">Men who have received prior docetaxel</span><span class="headingEndMark"> — </span>For most men who have progressed while receiving a docetaxel-based regimen for CRPC and who can tolerate it, we suggest <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> rather than other systemic therapy options, including either <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> or an androgen-signaling-targeted treatment. When cabazitaxel is used, we recommend a dose of 20 mg/m<sup>2</sup> rather than 25 mg/m<sup>2</sup>. Prophylaxis with colony-stimulating factors may be indicated to prevent febrile neutropenia for patients older than 65 years, for those with extensive prior radiation therapy (RT), and in other high-risk groups. In addition, premedication with a glucocorticoid and an H1 as well as H2 receptor antagonist is generally recommended prior to each dose to prevent infusion reactions. (See  <a class="medical medical_review" href="/z/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy", section on 'Cabazitaxel'</a>.)</p><p>For patients who are not candidates for <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a>, <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> or platinum-based regimens are appropriate alternatives.</p><p>Men with high-volume metastatic castration-sensitive disease who have been treated with concurrent ADT and an 18-week course of <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> (based on the results of the CHAARTED and STAMPEDE trials) and who subsequently progress with CRPC and require additional chemotherapy can be treated with <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> or retreated with docetaxel. Retreatment with docetaxel may be more likely to be effective if the progression occurred a period of time after the initial docetaxel-based chemohormonal therapy; however, neuropathy may be dose limiting.</p><p class="headingAnchor" id="H3683995269"><span class="h3">Cabazitaxel</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">Cabazitaxel</a> is a semisynthetic taxane derivative that was developed for its activity in patients with resistance to <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> and is the preferred chemotherapy agent for patients previously treated with docetaxel. (See  <a class="medical medical_review" href="/z/d/html/85678.html" rel="external">"Treatment protocols for castration-resistant prostate cancer", section on 'Cabazitaxel and prednisone'</a>.)</p><p class="headingAnchor" id="H2320756717"><span class="h4">Cabazitaxel versus mitoxantrone</span><span class="headingEndMark"> — </span>The benefits of <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> over second-line treatment with <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> were initially shown in the phase III TROPIC trial, in which 755 men progressing on <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> were randomly assigned to oral prednisone (10 mg daily) and either cabazitaxel (25 mg/m<sup>2</sup> intravenously every three weeks) or mitoxantrone (12 mg/m<sup>2</sup> intravenously every three weeks) [<a href="#rid21">21</a>]. Premedication to prevent severe infusion reactions included glucocorticoids and both an H1 and an H2 receptor antagonist.</p><p>Men treated with <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> had increased overall survival compared with those treated with <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> plus prednisone (hazard ratio [HR] 0.70, 95% CI 0.59-0.83, median survival 15.1 versus 12.7 months). Progression-free survival was also significantly prolonged (2.8 versus 1.4 months, HR 0.74, 95% CI 0.64-0.86). On subset analysis, the survival benefit was greater in patients who had been most heavily exposed to <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> compared with those with the lowest exposure (HR 0.51 versus 0.96 for those who had received &gt;900 mg/m<sup>2</sup> versus those who had received &lt;225 mg/m<sup>2</sup>). With additional follow-up, there was a greater likelihood of surviving two or more years with cabazitaxel (27 versus 16 percent) [<a href="#rid22">22</a>].</p><p>The <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> regimen was significantly more toxic than <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a>. Potential treatment-related deaths were more frequent in the 30 days after last treatment for cabazitaxel compared with mitoxantrone (4.9 versus 2.4 percent). Grade 3 or greater neutropenia was observed in 82 percent of patients with cabazitaxel, and febrile neutropenia was seen in 8 percent. In addition, diarrhea was reported in 47 percent of patients and was grade ≥3 in 6 percent.</p><p>Prophylaxis with colony-stimulating factors is indicated to prevent febrile neutropenia for patients older than 65 years and for those with extensive prior RT, as well as in other high-risk groups. In addition, prophylaxis to prevent infusion reactions is recommended. (See  <a class="medical medical_review" href="/z/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy"</a>.)</p><p class="headingAnchor" id="H4290678059"><span class="h4">Third-line cabazitaxel versus androgen signaling therapy</span><span class="headingEndMark"> — </span>The superiority of third-line <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> over androgen-signaling therapy (<a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> or <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a>) in 255 men with metastatic CRPC previously treated with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> who had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) was shown in the phase III CARD trial [<a href="#rid23">23</a>]. Cabazitaxel was administered at a dose of 25 mg/m<sup>2</sup> every three weeks with daily <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> and G-CSF support. At a median follow-up of 9.2 months, third-line cabazitaxel improved imaging-based progression or death (74 versus 80 percent), median overall survival (13.6 versus 11 months), PSA response (36 versus 14 percent), and objective tumor response (37 versus 12 percent). Grade ≥3 adverse events occurred in a similar percentage of patients in both groups (56 versus 52 percent), although those that occurred more frequently with cabazitaxel were asthenia/fatigue (4 versus 2.4 percent) and diarrhea, peripheral neuropathy, and febrile neutropenia (for all categories, 3.2 percent versus none).</p><p>In a later analysis those who received third-line <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> rather than <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> or <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> also had better pain response rates and time to pain progression, fewer symptomatic skeletal events (19 versus 28 percent), and a longer time to deterioration of FACT-P (Functional Assessment of Cancer Therapy-Prostate) scores [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H1726330151"><span class="h4">Dose of cabazitaxel</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> was originally approved at a dose of 25 mg/m<sup>2</sup>, the preferred dose is 20 mg/m<sup>2</sup>, based on similar overall survival and decreased toxicity.</p><p>In the phase III noninferiority PROSELICA trial, 1200 men who had progressed on <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> were randomly assigned to <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> at 20 or 25 mg/m<sup>2</sup> [<a href="#rid25">25</a>]. Patients in both arms were treated every three weeks in conjunction with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for up to 10 cycles. The primary endpoint was overall survival.</p><p class="bulletIndent1"><span class="glyph">●</span>Median overall survival was similar at 20 and 25 mg/m<sup>2</sup> (13.4 versus 14.5 months, HR 1.024, upper limit of the 98.8% CI 1.184) and fulfilled the predefined noninferiority conditions in the trial's statistical plan. An upper limit of 1.214 was chosen as the noninferiority margin to maintain at least 50 percent of the 2.4-month survival benefit of <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> 25 mg/m<sup>2</sup> versus <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> that was observed in the TROPIC trial above. (See <a class="local">'Cabazitaxel versus mitoxantrone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The overall incidence of grade 3/4 adverse events was significantly decreased at the 20 mg/m<sup>2</sup> dose level (39.7 versus 54.5 percent). Similarly, the incidence of grade 4 neutropenia was decreased (21.3 versus 48.6 percent), as was the incidence of neutropenic sepsis and infection (2.2 versus 6.1 percent).</p><p></p><p>If the 25 mg/m<sup>2</sup> dose of <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> is chosen, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F201023s024lbl.pdf&amp;token=9NOW%2BAvcntpmpKj%2BsRUKenWfRF75zsYowV%2B5Im%2FLFqGf%2FHlV62yk2CRmmt67v8pw7cKBf%2Fm9gmtZ9GCBpc5SD%2FD5h0JtTFVjMfJ8AbJxHuo%3D&amp;TOPIC_ID=6945" target="_blank">the United States Prescribing Information for cabazitaxel</a> recommends primary prophylaxis with granulocyte colony stimulating factors. Prophylaxis with colony-stimulating factors is also indicated to prevent febrile neutropenia for patients older than 65 years, for those with extensive prior RT, and in other high-risk groups, even if they are receiving the 20 mg/m<sup>2</sup> dose.</p><p class="headingAnchor" id="H1146705636"><span class="h3">Docetaxel retreatment</span><span class="headingEndMark"> — </span>Increasingly, men with high-volume metastatic castration-sensitive disease are being offered ADT plus concurrent systemic therapy, often an 18-week course of <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, based on the results of the CHAARTED and STAMPEDE trials.</p><p>For men who subsequently progress with CRPC and require additional chemotherapy, retreatment with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> can be an option [<a href="#rid26">26,27</a>]. Retreatment may be more likely to be effective in men who have a docetaxel-free interval of &gt;3 months [<a href="#rid26">26</a>], although cumulative neuropathy may be dose limiting.</p><p class="headingAnchor" id="H15661182"><span class="h3">Other chemotherapy regimens</span><span class="headingEndMark"> — </span>There are no chemotherapy regimens that have an established role, based on randomized clinical trials, for patients who have progressed on the standard <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>/<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> regimen and <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a>. However, many of these patients may be candidates for additional chemotherapy when their disease cannot be managed with secondary endocrine therapies. (See  <a class="medical medical_review" href="/z/d/html/6942.html" rel="external">"Alternative endocrine therapies for castration-resistant prostate cancer"</a>.)</p><p class="headingAnchor" id="H1216249881"><span class="h4">Platinum-based regimens</span><span class="headingEndMark"> — </span>Platinum agents have some antitumor activity in metastatic CRPC [<a href="#rid28">28</a>]. The most widely used contemporary regimens for docetaxel-resistant disease incorporate a platinum compound (<a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>), often in conjunction with <a class="drug drug_general" data-topicid="9423" href="/z/d/drug information/9423.html" rel="external">estramustine</a>, <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>, or <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>.</p><p class="headingAnchor" id="H1216249782"><span class="h5">Carboplatin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">Carboplatin</a> had some clinical activity against CRPC in relatively small phase II trials that were conducted prior to the development of the standard <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>/<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> regimen [<a href="#rid29">29-33</a>].</p><p>The potential role of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> is illustrated by three contemporary phase II studies limited to patients who had progressed on <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>The combination of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> was evaluated in 38 patients, 24 of whom had received two or more prior chemotherapy regimens [<a href="#rid34">34</a>]. A clinical and/or biochemical response was seen in 26 percent of cases, and an additional 34 percent had stable disease. The median duration of response and the median time to progression were 6 and 3.6 months, respectively, and the median overall survival was 10 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second phase II study, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> was given in combination with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> to 34 men who had progressed during or within 45 days after the completion of docetaxel-based chemotherapy [<a href="#rid19">19</a>]. Biochemical responses were observed in 18 percent of cases, median progression-free survival was three months, and median overall survival was 12 months.</p><p></p><p>Data on combined <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> for patients with aggressive variant prostate cancer are discussed below. (See <a class="local">'Aggressive prostate cancer variants'</a> below.)</p><p class="headingAnchor" id="H1216249940"><span class="h5">Oxaliplatin</span><span class="headingEndMark"> — </span>The clinical activity of <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> was initially suggested in a phase II study in which oxaliplatin was combined with infusional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> in men with CRPC [<a href="#rid35">35</a>].</p><p>Two subsequent studies have evaluated the combinations using <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> in men who progressed after docetaxel-based chemotherapy:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 47 men, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> was combined with <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">pemetrexed</a> [<a href="#rid36">36</a>]. A biochemical (PSA) response was observed in 64 percent of cases, and an objective response was seen in 10 of the 40 men with measurable disease. Median progression-free survival was six months, and median overall survival was 12 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another phase II study, 14 men were treated with the combination of <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> [<a href="#rid37">37</a>]. A PSA response was observed in 8 of 14 cases (57 percent), and median overall survival was 24 weeks.</p><p></p><p class="headingAnchor" id="H1216249952"><span class="h5">Cisplatin</span><span class="headingEndMark"> — </span>Older trials suggested that <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> has some activity in combination with either an anthracycline [<a href="#rid38">38</a>] or with <a class="drug drug_general" data-topicid="9423" href="/z/d/drug information/9423.html" rel="external">estramustine</a> plus <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> [<a href="#rid39">39</a>] in men with CRPC.</p><p>In a phase II study, 25 men who had docetaxel-refractory disease were treated with the combination of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid40">40</a>]. Biochemical responses were observed in 20 percent of cases, and 3 of the 13 patients with measurable disease had a partial response. Median progression-free survival was six months, and median overall survival was 55 weeks.</p><p class="headingAnchor" id="H1216250121"><span class="h4">Other agents</span></p><p class="headingAnchor" id="H66810582"><span class="h5">Mitoxantrone</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> is approved for the treatment of men with advanced prostate cancer, the approval was based on symptom palliation and not an increase in overall survival in men with CRPC [<a href="#rid41">41-43</a>].</p><p><a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">Mitoxantrone</a> retains some activity in patients who have progressed on <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, although the availability of <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> and other agents that prolong survival minimizes its role in this setting. In the phase III trial comparing cabazitaxel with mitoxantrone in patients who had previously been treated with docetaxel, mitoxantrone had a 4 percent objective response rate and an 18 percent PSA response rate [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H15661271"><span class="h5">Paclitaxel</span><span class="headingEndMark"> — </span>The taxane <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> has been less extensively evaluated than <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> in men with CRPC. Paclitaxel does not have an established role in these patients but appears to have activity that is schedule dependent [<a href="#rid34">34,44</a>]. Experience in men with docetaxel-refractory disease comes primarily from combinations with platinum compounds. (See <a class="local">'Platinum-based regimens'</a> above.)</p><p class="headingAnchor" id="H2288840771"><span class="h2">Aggressive prostate cancer variants</span></p><p class="headingAnchor" id="H3609366576"><span class="h3">Definition</span><span class="headingEndMark"> — </span>Pure small cell or neuroendocrine carcinomas of the prostate are rare at initial diagnosis (≤2 percent of cases [<a href="#rid45">45</a>]), and they have a dismal prognosis, with most patients dying within one year, despite their sensitivity to platinum-based cytotoxic chemotherapy. They are treated in a manner similar to other extrapulmonary small cell cancers. (See  <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">"Interpretation of prostate biopsy", section on 'Neuroendocrine neoplasms'</a> and  <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">"Localized prostate cancer: Risk stratification and choice of initial treatment", section on 'High-grade, low-PSA prostate cancer'</a> and  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer", section on 'Treatment'</a>.)</p><p>More commonly, neuroendocrine differentiation may also emerge in men who have previously had ADT for prostate adenocarcinoma. Autopsy series demonstrate the presence of neuroendocrine differentiation in 10 to 20 percent of men dying of CRPC [<a href="#rid46">46-48</a>]. These tumors, sometimes called treatment-related neuroendocrine prostate cancers or aggressive-variant prostate cancers (AVPCs), are increasingly recognized in the castration-resistant phases of disease progression.</p><p>The underlying biology evolves due to the selective pressure of hormone therapy, especially with potent androgen receptor pathway inhibitors, with loss of dependence on androgen receptor signaling. These tumors can be androgen receptor negative, have a varying degree of small cell carcinoma morphology (or mixed small cell and adenocarcinoma), and can express markers of neuroendocrine differentiation (eg, chromogranin, synaptophysin) [<a href="#rid49">49-51</a>]. In addition, they can be associated with low PSA production and with an aggressive clinical course with atypical clinical manifestations, and they are relatively resistant to androgen-signaling inhibitors.</p><p>Investigators from MD Anderson Cancer Center utilized a series of 114 patients to prospectively develop seven clinical criteria to identify AVPC  (<a class="graphic graphic_table graphicRef122053" href="/z/d/graphic/122053.html" rel="external">table 1</a>) [<a href="#rid52">52</a>].</p><p>These investigators also showed that the presence of at least one of these clinical features in a man with CRPC was associated with a high response rate to <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, irrespective of morphology. (See <a class="local">'Treatment'</a> below.)</p><p>Molecular characterization of tumor tissues (and circulating tumor DNA) from patients who met the clinical criteria for AVPC revealed defects in one or more of the tumor suppressors <em>TP53</em> (tumor protein 53), <em>RB1</em> (retinoblastoma 1), <em>PTEN</em> (phosphatase and tensin homolog) [<a href="#rid53">53-55</a>]. The biologic significance of this molecular signature is supported by its association with lineage plasticity and androgen indifference in preclinical studies [<a href="#rid56">56-58</a>].</p><p class="headingAnchor" id="H2772658977"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>The optimal way to manage patients with AVPC is not established. We prefer that patients be enrolled in clinical trials testing new strategies. If trial participation is not available or is declined, we have used <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> in combination with <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> (if cabazitaxel was not previously used). Another approach is to use the drugs sequentially rather than in combination. Others have shown benefit with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> plus carboplatin.</p><p>There are few randomized trials to guide management of patients with aggressive-variant CRPC, and clinical studies are sparse. Patients with tumors that contain essentially neuroendocrine features (for instance, pure primary small cell cancers) can respond to chemotherapy regimens that are used for small cell cancer involving the lung (eg, platinum/<a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> combinations), with response rates that vary from 10 to 50 percent [<a href="#rid52">52,59,60</a>]. (See  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>.)</p><p>Guidelines from the National Comprehensive Cancer Network (NCCN) suggest a combination of <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> with either <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> in patients with pure small cell carcinoma of the prostate. To what extent this recommendation is applicable to treatment-emergent (post-ADT, with or without prior taxane treatment) AVPC with a neuroendocrine-differentiated component is not clear.</p><p>At times, we have used <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> in combination with <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> in this setting, and there is some preliminary evidence to support the efficacy of this combination. One randomized phase II trial directly compared cabazitaxel alone versus cabazitaxel plus carboplatin in 160 men with CRPC (87 of whom met at least one of the clinicopathologic criteria for AVPC  (<a class="graphic graphic_table graphicRef122053" href="/z/d/graphic/122053.html" rel="external">table 1</a>)) [<a href="#rid61">61</a>]. In the entire cohort, median progression-free survival (the primary endpoint) was significantly greater with combined therapy (7.3 versus 4.5 months, HR 0.69, 95% CI 0.5-0.95), and the partial response rate was also higher (57 versus 23 percent). The incidence of serious adverse events was also higher with combined therapy (40 versus 22 percent, mostly fatigue, nausea, dehydration, and myelosuppression). In a prespecified subgroup analysis based on stratification factors at baseline, the benefit of combined therapy was greater in men with AVPC (HR 0.58, 95% CI 0.37-0.89), but the test for interaction was not statistically significant in the intent-to-treat population.</p><p>Given the toxicity of the combination regimen and the limited progression-free survival benefit, another approach is to use these drugs sequentially rather than in combination. Others have used <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> plus <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> [<a href="#rid52">52</a>]. We urge clinical trial participation if feasible (eg, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03263650%3Fcond%3DNeuroendocrine%2Bprostate%2Bcancer%26draw%3D2%26rank%3D16&amp;token=U43uT8U9uvsW5UbAtfudsFHQW9%2FI85mYd%2BUL6Y6m1RIY4aoYAIKMyLi2soGR19g7F7TqzQpZen%2B3lAAyb5xSQ6oLh5XeCZb60TNmSiLuHwtS%2BX2ZwcKpOrKgmrN55xMoXM%2FgoGe%2BRJrLHzlBRf7x4A%3D%3D&amp;TOPIC_ID=6945" target="_blank">NCT03263650</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03582475%3Fcond%3DNeuroendocrine%2Bprostate%2Bcancer%26draw%3D2%26rank%3D10&amp;token=WVCc%2FILR6JMWdLjcUb4iAwxOKSHogJyw86wq8Jj4r3CfSq0g%2FEWYXh0Ya7RwXdyNWhohMZmcLnH51H2oF0JUu%2FSY6WPILLQEHCUsIJyBpigmMhcBvGyJ7IYGm9majLkn1ug%2BM6lL2Jh2cxdVCkCLtA%3D%3D&amp;TOPIC_ID=6945" target="_blank">NCT03582475</a>).</p><p>Overall, prognosis is poor, with a median survival of only 9 to 17 months [<a href="#rid45">45,60,62-64</a>]. Molecular phenotyping for various potentially targetable alterations is emerging as a therapeutic approach in these patients. (See  <a class="medical medical_review" href="/z/d/html/128308.html" rel="external">"Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/6937.html" rel="external">"Immunotherapy for castration-resistant prostate cancer"</a>.)</p><p class="headingAnchor" id="H2004926540"><span class="h1">MEN WITH HOMOLOGOUS RECOMBINATION REPAIR GENE ABERRATIONS</span><span class="headingEndMark"> — </span>A proportion of men with advanced prostate cancer can harbor deleterious germline or somatic mutations in homologous recombination repair (HRR) genes. As an example, analyses of clinical cohorts of men have revealed germline DNA repair mutations in approximately 12 percent of those with metastatic prostate cancer [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/112282.html" rel="external">"Genetic risk factors for prostate cancer", section on 'Heritable factors'</a>.)</p><p>The identification of a germline mutation in <em>BRCA2</em> (breast cancer susceptibility 2) or in other DNA repair genes (<em>BRCA1</em> [breast cancer susceptibility 1], <em>ATM</em> [ataxia telangiectasia mutated], <em>PALB2</em> [partner and localizer of <em>BRCA2</em>], <em>RAD51</em> or<em> RAD54</em>, <em>CHEK2</em> [checkpoint kinase 2]), or of a somatic mutation in these genes that is found using next-generation sequencing of tumor tissue has implications for chemotherapy treatment in men with metastatic prostate cancer.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platinum-based chemotherapy</strong> – Platinum agents lead to DNA interstrand crosslinks, which can often be processed by homologous recombination. However, <em>BRCA</em>-mutant tumors are defective in DNA repair by homologous recombination (ie, they are HRR deficient), leading to a unique sensitivity to platinum agents.</p><p></p><p class="bulletIndent1">Retrospective data suggest a high probability of response to platinum-based chemotherapy in metastatic CRPC with HRR deficiency, similar to breast, ovarian, and pancreatic cancer.</p><p></p><p class="bulletIndent1">Patients with metastatic CRPC who have pathogenic or likely pathogenic variants in HRR genes such as <em>BRCA</em>, <em>ATM</em>, <em>PALB2</em>, <em>FANCA </em>(Fanconi anemia complementation group A), <em>RAD51D</em>, and <em>CHEK2</em> to be candidates for early use of platinum-based chemotherapy. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/128308.html" rel="external">"Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency", section on 'Platinum-containing chemotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PARP inhibitors</strong> – Poly(ADP-ribose) polymerase (PARP) inhibitors block the repair of DNA single-strand breaks, and as tumors associated with <em>BRCA</em> mutations become more dependent on single-strand DNA repair pathways, PARP inhibitors lead to cell death due to the inefficiencies in cell repair mechanisms in such tumors.</p><p></p><p class="bulletIndent1">PARP inhibitors have demonstrated activity in men who have metastatic CRPC and pathogenic or likely pathogenic germline or somatic variants in DNA repair genes leading to HRR deficiency (especially <em>BRCA2</em>). Two of these agents are now approved for advanced CRPC with HRR deficiency and are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/128308.html" rel="external">"Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency", section on 'Benefit of PARP inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H16667470"><span class="h1">MEN WITH DEFICIENT DNA MISMATCH REPAIR OR HIGH LEVELS OF TUMOR MUTATIONAL BURDEN</span><span class="headingEndMark"> — </span>Patients whose tumors harbor a loss of one of the DNA mismatch repair enzymes (ie, <em>MLH1</em>, <em>PMS2</em>, <em>MSH2</em> or <em>MSH6</em>) or demonstrate high levels of TMB (≥10 mutations per megabase [mut/Mb] on tissue-based testing) may be candidates for checkpoint inhibitor immunotherapy (see  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>). TMB measurements in the context of circulating tumor DNA assays are unclear given lack of vigorous study.</p><p class="headingAnchor" id="H2929221459"><span class="h1">ASSESSMENT DURING TREATMENT</span><span class="headingEndMark"> — </span>For men with CRPC who are undergoing chemotherapy, periodic assessment should be geared toward identifying signs and symptoms of disease progression, as well as the side effects of treatment. Serial evaluation of serum prostate-specific antigen (PSA) is the mainstay of testing. Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) recommend testing PSA at least every three to six months during treatment for advanced prostate cancer [<a href="#rid66">66</a>]; however, more frequent monitoring is typical in contemporary practice. Most clinicians make decisions about the need for radiographic evaluation based on changes in PSA values and/or the development of new symptoms. Therapeutic changes are usually not made based on a rising PSA alone.</p><p>Assessment strategies during treatment for CRPC are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">"Overview of the treatment of castration-resistant prostate cancer (CRPC)", section on 'Assessment during treatment'</a>.)</p><p class="headingAnchor" id="H1643461991"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117831.html" rel="external">"Society guideline links: Diagnosis and management of prostate cancer"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/880.html" rel="external">"Patient education: Treatment for advanced prostate cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Germline and somatic genomic testing</strong> – For patients with metastatic CRPC who may be potential candidates for targeted therapies, both germline genomic testing (if not already known) and somatic genomic testing should be undertaken because of the significant treatment implications, particularly of finding alterations in homologous recombination repair (HRR) genes. (See <a class="local">'Germline and targeted tumor genomic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Men without neuroendocrine features or DNA repair abnormalities</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For men with chemotherapy-naïve castration-resistant prostate cancer (CRPC) without neuroendocrine (small cell) features or alterations in a HRR gene who are candidates for cytotoxic chemotherapy, we suggest <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> plus oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>  (<a class="graphic graphic_table graphicRef57477" href="/z/d/graphic/57477.html" rel="external">table 2</a>) rather than <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> plus prednisone (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>).</p><p></p><p class="bulletIndent2">Another reasonable option is <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a>. Although we generally prefer <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> over cabazitaxel as the initial chemotherapy regimen for CRPC, cabazitaxel  (<a class="graphic graphic_table graphicRef82196" href="/z/d/graphic/82196.html" rel="external">table 3</a>) may be preferred in older or frail patients and those at high risk for neutropenia, based on its lower toxicity and similar efficacy, despite its higher cost. (See <a class="local">'Docetaxel versus cabazitaxel'</a> above.)</p><p></p><p class="bulletIndent2">Another alternative for patients in whom myelosuppression is of particular concern is administration of a lower <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> dose (50 mg/m<sup>2</sup>) every two weeks or the addition of a granulocyte colony-stimulating factor (G-CSF) to standard every-three-week docetaxel. (See <a class="local">'Alternative docetaxel schedules'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gonadal androgen suppression, but not antiandrogens, should be continued during chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/6942.html" rel="external">"Alternative endocrine therapies for castration-resistant prostate cancer", section on 'Continuation of androgen deprivation therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with CRPC that has progressed on treatment with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, a number of treatment options have been shown to prolong overall survival  (<a class="graphic graphic_table graphicRef127197" href="/z/d/graphic/127197.html" rel="external">table 4</a>). (See <a class="local">'Men who have received prior docetaxel'</a> above and  <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">"Overview of the treatment of castration-resistant prostate cancer (CRPC)"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most men who can tolerate it, we suggest <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a>  (<a class="graphic graphic_table graphicRef82196" href="/z/d/graphic/82196.html" rel="external">table 3</a>) over other systemic therapy options, including <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> and androgen-signaling-targeted therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Cabazitaxel versus mitoxantrone'</a> above and <a class="local">'Third-line cabazitaxel versus androgen signaling therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who are not candidates for <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a>, <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or platinum-based regimens are appropriate alternatives. (See <a class="local">'Other agents'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Men with high-volume metastatic castration-sensitive disease who have been treated with concurrent androgen deprivation therapy (ADT) and an 18-week course of <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> (based on the results of the CHAARTED and STAMPEDE trials) and who subsequently progress to CRPC and require additional chemotherapy can be treated with <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> or retreated with docetaxel. Retreatment with docetaxel may be more likely to be effective if the progression occurred a period of time after the initial docetaxel-based chemohormonal therapy. (See <a class="local">'Docetaxel retreatment'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For men who are treated with an androgen-signaling-targeted therapy rather than <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> after progression on first-line <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, third-line cabazitaxel is an option. (See <a class="local">'Third-line cabazitaxel versus androgen signaling therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small cell neuroendocrine tumors</strong> – Neuroendocrine differentiation may emerge in men who have previously had ADT for prostate adenocarcinoma (aggressive-variant prostate cancer [AVPC]). The best regimen for tumors that have some features of neuroendocrine differentiation but are not pure small cell cancers (eg, AVPC) is not established. Some patients may benefit from a taxane/platinum combination. (See <a class="local">'Aggressive prostate cancer variants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Men with HRR gene alterations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Men who have metastatic CRPC and either a germline or somatic mutation in a DNA repair gene (eg, <em>BRCA</em> [breast cancer susceptibility], <em>PALB2</em> [partner and localizer of <em>BRCA2</em>], or <em>ATM</em> [ataxia telangiectasia mutated]) are appropriate candidates for early use of a PARP inhibitor and/or a platinum-based chemotherapy regimen. (See <a class="local">'Men with homologous recombination repair gene aberrations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Men with deficient mismatch repair or high TMB</strong> – Patients whose tumors harbor a loss of one of the DNA mismatch repair enzymes (ie, <em>MLH1, PMS2, MSH2 or MSH6</em>) or high levels of tumor mutational burden (TMB, ≥10 mutations per megabase [mut/Mb]) may be candidates for checkpoint inhibitor immunotherapy. Specific recommendations are provided separately. (See  <a class="medical medical_review" href="/z/d/html/6937.html" rel="external">"Immunotherapy for castration-resistant prostate cancer", section on 'PD-1 pathway inhibition'</a>.)</p><p></p><p class="headingAnchor" id="H429086432"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>We are saddened by the death of Nicholas Vogelzang, MD, who passed away in September 2022. UpToDate gratefully acknowledges Dr. Vogelzang's role as Section Editor on this topic, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol 2020; 38:3217.</a></li><li><a class="nounderline abstract_t">Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022; 40:1231.</a></li><li><a class="nounderline abstract_t">Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014; 32:3436.</a></li><li><a class="nounderline abstract_t">Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502.</a></li><li><a class="nounderline abstract_t">Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242.</a></li><li><a class="nounderline abstract_t">Haines IE, Stanley RM. Perspective on "Chemotherapy for advanced prostate cancer: 25 years later": is it a mirage or an oasis? J Clin Oncol 2008; 26:4049.</a></li><li><a class="nounderline abstract_t">Weitzman AL, Shelton G, Zuech N, et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 2000; 163:834.</a></li><li><a class="nounderline abstract_t">Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013; 14:117.</a></li><li><a class="nounderline abstract_t">Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30:1534.</a></li><li><a class="nounderline abstract_t">Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013; 14:760.</a></li><li><a class="nounderline abstract_t">Petrylak DP, Vogelzang NJ, Budnik N, et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2015; 16:417.</a></li><li><a class="nounderline abstract_t">Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 2013; 14:1307.</a></li><li><a class="nounderline abstract_t">Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 2013; 14:893.</a></li><li><a class="nounderline abstract_t">Fizazi K, Higano CS, Nelson JB, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013; 31:1740.</a></li><li><a class="nounderline abstract_t">Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011; 29:2191.</a></li><li><a class="nounderline abstract_t">Hahn NM, Marsh S, Fisher W, et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 2006; 12:6094.</a></li><li><a class="nounderline abstract_t">Ferrero JM, Chamorey E, Oudard S, et al. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 2006; 107:738.</a></li><li><a class="nounderline abstract_t">Petrioli R, Paolelli L, Francini E, et al. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology 2007; 69:142.</a></li><li><a class="nounderline abstract_t">Ross RW, Beer TM, Jacobus S, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008; 112:521.</a></li><li><a class="nounderline abstract_t">Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol 2017; 35:3189.</a></li><li><a class="nounderline abstract_t">de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147.</a></li><li><a class="nounderline abstract_t">Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013; 24:2402.</a></li><li><a class="nounderline abstract_t">de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med 2019; 381:2506.</a></li><li><a class="nounderline abstract_t">Fizazi K, Kramer G, Eymard JC, et al. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncol 2020; 21:1513.</a></li><li><a class="nounderline abstract_t">Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol 2017; 35:3198.</a></li><li><a class="nounderline abstract_t">Thomas C, Brandt MP, Baldauf S, et al. Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival. Int Urol Nephrol 2018; 50:1821.</a></li><li><a class="nounderline abstract_t">Di Lorenzo G, Pagliuca M, Perillo T, et al. Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature. Medicine (Baltimore) 2016; 95:e2754.</a></li><li><a class="nounderline abstract_t">Hager S, Ackermann CJ, Joerger M, et al. Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. Ann Oncol 2016; 27:975.</a></li><li><a class="nounderline abstract_t">Thall PF, Logothetis C, Pagliaro LC, et al. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst 2007; 99:1613.</a></li><li><a class="nounderline abstract_t">Berry W, Friedland D, Fleagle J, et al. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006; 5:131.</a></li><li><a class="nounderline abstract_t">Kikuno N, Urakami S, Nakamura S, et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 2007; 51:1252.</a></li><li><a class="nounderline abstract_t">Cabrespine A, Guy L, Khenifar E, et al. Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Urology 2006; 67:354.</a></li><li><a class="nounderline abstract_t">Segawa T, Kamoto T, Kinoshita H, et al. Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. Int J Clin Oncol 2005; 10:333.</a></li><li><a class="nounderline abstract_t">Kentepozidis N, Soultati A, Giassas S, et al. Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. Cancer Chemother Pharmacol 2012; 70:161.</a></li><li><a class="nounderline abstract_t">Droz JP, Muracciole X, Mottet N, et al. Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol 2003; 14:1291.</a></li><li><a class="nounderline abstract_t">Dorff TB, Tsao-Wei DD, Groshen S, et al. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2013; 11:416.</a></li><li><a class="nounderline abstract_t">Gasent Blesa JM, Giner Marco V, Giner-Bosch V, et al. Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients. Am J Clin Oncol 2011; 34:155.</a></li><li><a class="nounderline abstract_t">Huan SD, Stewart DJ, Aitken SE, et al. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am J Clin Oncol 1999; 22:471.</a></li><li><a class="nounderline abstract_t">Kaku H, Saika T, Tsushima T, et al. Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer. Acta Med Okayama 2006; 60:43.</a></li><li><a class="nounderline abstract_t">Buonerba C, Federico P, D'Aniello C, et al. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer Chemother Pharmacol 2011; 67:1455.</a></li><li><a class="nounderline abstract_t">Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756.</a></li><li><a class="nounderline abstract_t">Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506.</a></li><li><a class="nounderline abstract_t">Berry W, Dakhil S, Modiano M, et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002; 168:2439.</a></li><li><a class="nounderline abstract_t">Sewak S, Kosmider S, Ganju V, et al. Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting. Intern Med J 2010; 40:201.</a></li><li><a class="nounderline abstract_t">Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1:487.</a></li><li><a class="nounderline abstract_t">Turbat-Herrera EA, Herrera GA, Gore I, et al. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Arch Pathol Lab Med 1988; 112:1100.</a></li><li><a class="nounderline abstract_t">Tanaka M, Suzuki Y, Takaoka K, et al. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 2001; 8:431.</a></li><li><a class="nounderline abstract_t">Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64:9209.</a></li><li><a class="nounderline abstract_t">Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 2014; 20:2846.</a></li><li><a class="nounderline abstract_t">Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov 2011; 1:466.</a></li><li><a class="nounderline abstract_t">Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 2014; 38:756.</a></li><li><a class="nounderline abstract_t">Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013; 19:3621.</a></li><li><a class="nounderline abstract_t">Aparicio AM, Shen L, Tapia EL, et al. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 2016; 22:1520.</a></li><li><a class="nounderline abstract_t">Beltran H, Romanel A, Conteduca V, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest 2020; 130:1653.</a></li><li><a class="nounderline abstract_t">Corn PG, Tapia EL, Xiao L, et al. Confirmatory analysis to determine associations between platinum-sensitivity, molecular signature of combined tumor suppressor defects and aggressive variant prostate carcinomas (AVPC). J Clin Oncol 2016; 34S:ASCO #5020.</a></li><li><a class="nounderline abstract_t">Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 2017; 355:78.</a></li><li><a class="nounderline abstract_t">Mu P, Zhang Z, Benelli M, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 2017; 355:84.</a></li><li><a class="nounderline abstract_t">Zou M, Toivanen R, Mitrofanova A, et al. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. Cancer Discov 2017; 7:736.</a></li><li><a class="nounderline abstract_t">Fléchon A, Pouessel D, Ferlay C, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011; 22:2476.</a></li><li><a class="nounderline abstract_t">Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002; 20:3072.</a></li><li><a class="nounderline abstract_t">Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 2019; 20:1432.</a></li><li><a class="nounderline abstract_t">Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol 2018; 36:2492.</a></li><li><a class="nounderline abstract_t">Spiess PE, Pettaway CA, Vakar-Lopez F, et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 2007; 110:1729.</a></li><li><a class="nounderline abstract_t">Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 1992; 147:804.</a></li><li><a class="nounderline abstract_t">Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 2016; 375:443.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on August 15, 2019).</li></ol></div><div id="topicVersionRevision">Topic 6945 Version 63.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32755482" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Metastatic Pancreatic Cancer: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25199761" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15470213" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182665" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711202" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Perspective on "Chemotherapy for advanced prostate cancer: 25 years later": is it a mirage or an oasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10687988" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23294853" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22454414" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23742877" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25743937" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24211163" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23871417" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23569308" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21483004" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062685" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16826591" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17270637" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18085595" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28753384" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888992" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23723295" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566937" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926841" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28809610" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30120678" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27057826" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27052650" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17971530" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17026801" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17208356" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16442593" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16247660" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22660737" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12881395" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24099865" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20539209" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10521061" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508688" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21365219" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8656243" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561316" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12441935" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19460063" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22389870" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2460064" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555007" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Progression of prostate cancer to neuroendocrine cell tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15604294" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24727321" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Aggressive variants of castration-resistant prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22586648" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Understanding the lethal variant of prostate cancer: power of examining extremes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705311" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23649003" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Platinum-based chemotherapy for variant castrate-resistant prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26546618" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32091413" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Confirmatory analysis to determine associations between platinum-sensitivity, molecular signature of combined tumor suppressor defects and aggressive variant prostate carcinomas (AVPC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28059767" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28059768" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28411207" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21436186" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118020" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515154" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985747" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17786954" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment outcomes of small cell carcinoma of the prostate: a single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1311395" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27433846" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
